Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
April 26, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List
April 19, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
March 10, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
March 08, 2022 16:05 ET
|
Evoke Pharma, Inc.
Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare...
Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
March 01, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022
February 24, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal...
GIMOTI® Commercialization Update
February 17, 2022 08:30 ET
|
Evoke Pharma, Inc.
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent...
Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
February 02, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI)...
Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases,...
RPAR Risk Parity ETF, Another Tidal Successful Launch, Surpasses $1.5 Billion AUM
December 06, 2021 08:00 ET
|
Tidal ETF Services
CHICAGO and MILWAUKEE and NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Tidal ETF Services LLC (“Tidal”), an innovative leading provider of ETF services, announced today the RPAR Risk Parity ETF...